Telaprevir

Type: Keyphrase
Name: Telaprevir
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

Second Wave Anti-HCV Protease Inhibitors

Stella De Nicola, Alessio AghemoDisclosuresLiver International. 2014;34(7):e168-e170.Drug development for chronic hepatitis C is progressing at a furious rate; after more than 10 years spent at optimizing Pegylated Interferon and Ribavirin regimens, ... [Published General Medicine eJournal - Oct 17 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

New hepatitis C hopes

New drugs and treatments will enable GPs to take a more active role in treating the 200,000-plus Australians living with hepatitis C.Many people will have seen the movie Dallas Buyers Club recently, and will have been reminded of the early days of the ... [Published Australian Doctor - Oct 16 2014]
First reported Oct 10 2014 - Updated Oct 10 2014 - 3 reports

Janssen demonstrates continued commitment to combating Hepatitis C in European patients with data presented at Viral Hepatitis Congress

(Janssen) today announced the presentation of additional data for the NS3/4A protease inhibitor OLYSIO® (simeprevir) at the Viral Hepatitis Congress (VHC) in Frankfurt, Germany. The data includes new analysis of a European and Israeli Hepatitis C (HCV) ... [Published European Pharmaceutical Review - Oct 10 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 1 reports

Literatus: Updates on HCV

ONE advantage in using the medical lingo is the shorter word or phrase that provides info, compared to using conversational terms. The disadvantage: readers may not understand it. However, when do we start doing this, even a little each week? The favorite ... [Published Sun Star Network - Oct 07 2014]
First reported Sep 30 2014 - Updated Sep 30 2014 - 2 reports

Chronic Hepatitis C

Section Sponsored by:Chronic hepatitis C virus (HCV) infection is becoming the fastest growing cause of cancer-related death and the leading cause of liver transplantation among adults in the United States. 1 Experts estimate that between 1990 and 2015 ... [Published Advance for NPs and PAs - Sep 30 2014]
First reported Sep 28 2014 - Updated Sep 28 2014 - 1 reports

Global Sales of Hepatitis C Virus Market to Grow $12.8 billion by 2022...

MarketOptimizer.org adds “PharmaPoint: Hepatitis C Virus – Global Drug Forecast and Market Analysis to 2022 – Event-Driven Update” to its store. Hepatitis C Virus Market is expected to grow during the Forecast Period. The Hepatitis C Virus Market generated ... [Published PRWeb - Sep 28 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update, New Report Launched

Lewes, DE -- (SBWIRE) -- 09/26/2014 -- PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update report Provide Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute ... [Published Reliance Trust - Sep 26 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

Triple Therapy for Chronic HCV

Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29(Suppl 1): 74–81.Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med ... [Published General Medicine eJournal - Sep 26 2014]
First reported Sep 23 2014 - Updated Sep 24 2014 - 2 reports

Management of Hepatitis C Genotype 1 Monoinfection

Makia Dove, PharmD Candidate, Clarice Carthon, PharmD Candidate, Monika N. Daftary, PharmD, BCPS, AAHIVPDisclosuresUS Pharmacist. 2014;39(4):75-79.Abstract and Introduction AbstractHepatitis C is a common cause of end-stage liver disease in the United ... [Published General Medicine eJournal - Sep 24 2014]
First reported Sep 23 2014 - Updated Sep 23 2014 - 1 reports

Mitsubishi Tanabe receives approval for additional indication of HCV drug

Mitsubishi Tanabe Pharma Corporation has received approval for an additional indication of TELAVIC 250mg tablets, indicated for the treatment of chronic genotype 2 hepatitis C virus infection, or HCV. Telavic, an oral treatment of chronic hepatitis C, ... [Published Individual.com - Sep 23 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

LT recipients with HCV met SVR with telaprevir, PEG-IFN/RBV

NEW YORK — Liver transplant recipients with hepatitis C virus genotype 1 achieved sustained virologic response by 12 weeks of therapy with telaprevir plus pegylated interferon and ribavirin, according to data presented at the AASLD/EASL Special Conference ... [Published Orthopedics Today - Sep 15 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 2 reports

The Hepatitis C virus is the main cause of liver transplant in the world

/PRNewswire/ -- The Chemistry, Food & Drugs Division of the Trinidad & Tobago Ministry of Health approved the introduction of Telaprevir to the market, an innovative therapy that significantly increases the cure rate from Hepatitis C, and it is indicated ... [Published BioPortfolio - Jul 25 2014]

Quotes

The following quote was obtained by the news editors from the background information supplied by the inventors: "The HCV is an RNA virus belonging to the Hepacivirus genus in the Flaviviridae family. The enveloped HCV virion contains a positive stranded RNA genome encoding all known virus-specific proteins in a single, uninterrupted, open reading frame. The openopen reading frame comprises approximately 9500 nucleotides and encodes a single large polyprotein of about 3000 amino acids. The polyprotein comprises a core protein, envelope proteins E1 and E2, a membrane bound protein p7, and the non-structural proteins NS2, NS3, NS4A, NS4B, NS5A and NS5B."
"Current treatment of hepatitis C infection typically includes administration of an interferon, such as pegylated interferon (IFN), in combination with ribavirin. The success of current therapies as measured by sustained virologic response (SVR) depends on the strain of HCV with which the patient is infected and the patient's adherence to the treatment regimen. Only 50% of patients infected with HCV strain GT-1 exhibit a sustained virological response. Antiviral agents such as BI 201335 (Boehringer Ingelheim), TMC435 (Tibotec), Telaprevir (Vertex), and Boceprevir (Merck) may be used for treatment of chronic HCV, Several antiviral agents including ACH-1625, ACH-2684, ACH-2928, and ACH-3102 are in clinical development for treatment of chronic HCV. Each of these drugs may be used in combination with a compound of /Formula I, discussed below, and optionally in combination with an immune modulator, such as interferon, or an additional anti-viral agent. Due to lack of effective therapies for treatment for certain HCV strains and the high mutation rate of HCV, new therapies are needed. The present invention fulfills this need and provides additional advantages, which are described herein."

More Content

All (44) | News (33) | Reports (0) | Blogs (9) | Audio/Video (0) | Fact Sheets (1) | Press Releases (0)
sort by: Date | Relevance
Second Wave Anti-HCV Protease Inhibitors [Published General Medicine eJournal - Oct 17 2014]
New hepatitis C hopes [Published Australian Doctor - Oct 16 2014]
New Treatments for Hepatitis C [Published MedIndia - Oct 13 2014]
Janssen demonstrates continued commitment to co... [Published European Pharmaceutical Review - Oct 10 2014]
"Methods for Treating Hcv" in Patent Applicatio... [Published Pharmacy Choice - Oct 10 2014]
Janssen Demonstrates Continued Commitment to Co... [Published CNBC - Oct 10 2014]
Janssen Demonstrates Continued Commitment to -2- [Published Scottrade - Oct 10 2014]
HCV market forecast to total US$12.8Bn by 2022 [Published Live-PR.com - Oct 07 2014]
Literatus: Updates on HCV [Published Sun Star Network - Oct 07 2014]
Sovaldi ‘unaffordable’ says NHS documents [Published Pharmafocus - Oct 07 2014]
Chronic Hepatitis C [Published Advance for NPs and PAs - Sep 30 2014]
20 years since interferon was listed on the PBS... [Published Medianet - Sep 30 2014]
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Sep 29 2014]
Global Sales of Hepatitis C Virus Market to Gro... [Published PRWeb - Sep 28 2014]
Hepatitis C Virus - Global Drug Forecast and Ma... [Published Reliance Trust - Sep 26 2014]
Global Hepatitis C Virus Drug Industry to 2022 [Published MyNewsDesk - Sep 26 2014]
Triple Therapy for Chronic HCV [Published General Medicine eJournal - Sep 26 2014]
ACHILLION PHARMACEUTICALS : Patent Issued for N... [Published 4 Traders - Sep 25 2014]
Management of Hepatitis C Genotype 1 Monoinfection [Published General Medicine eJournal - Sep 24 2014]
NICE consults on draft guidance on the drug sim... [Published National AIDS Treatment Advocacy Project - Sep 23 2014]
Hepatitis C Therapeutics Market - Global Indust... [Published SBWire - Sep 23 2014]
Mitsubishi Tanabe receives approval for additio... [Published Individual.com - Sep 23 2014]
Treatments for Hepatitis C Are Too Expensive fo... [Published SBWire - Sep 23 2014]
Sovaldi: Discontinuation, trends, and rationing [Published The Incidental Economist (Posts) - Sep 23 2014]
Mitsubishi Tanabe Pharma gains approval for Tel... [Published Pharma Letter - Sep 22 2014]
Use of Protease Inhibitors in HIV/HCV Genotype ... [Published Diabetes Care - Sep 19 2014]
"Fighting an uphill battle": experience with th... [Published BMC - Sep 18 2014]
Johnson & Johnson: Slow And Steady Core Holding... [Published Seeking Alpha - Sep 17 2014]
LT recipients with HCV met SVR with telaprevir,... [Published Orthopedics Today - Sep 15 2014]
Ribavirin added to daclatasvir, sofosbuvir incr... [Published Orthopedics Today - Sep 15 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Sep 29 2014]
Sovaldi: Discontinuation, trends, and rationing [Published The Incidental Economist (Posts) - Sep 23 2014]
The following is a guest post by Allan Joseph, a medical student at the Warren Alpert Medical School of Brown University and TIE research assistant. You can follow Allan on Twitter: @allanmjoseph . You can read previous TIE coverage of Sovaldi here ...
The Hepatitis C virus is the main cause of live... [Published PR Newswire: General Business - Jul 25 2014]
PORT OF SPAIN, Trinidad and Tobago, July 25, 2014 /PRNewswire/ -- The Chemistry, Food & Drugs Division of the Trinidad & Tobago Ministry of Health approved the introduction of Telaprevir to the market, an innovative therapy that significantly increases ...
Treating Hepatitis C: Criticisms of sofosbuvir [Published The Incidental Economist (Posts) - Jun 17 2014]
The following is part of a series of guest posts on hepatitis C by Allan Joseph, a medical student at the Warren Alpert Medical School of Brown University and TIE research assistant. You can follow Allan on Twitter:  @allanmjoseph . Links to all posts ...
Treating Hepatitis C: Sofosbuvir [Published The Incidental Economist (Posts) - Jun 16 2014]
The following is part of a series of guest posts on hepatitis C by Allan Joseph, a medical student at the Warren Alpert Medical School of Brown University and TIE research assistant. You can follow Allan on Twitter:  @allanmjoseph . Links to all posts ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.